Just - Evotec Expands DoD Contract for Manufacturing Monoclonal Antibodie

 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the U.S. Department of

Defense ("DOD") awarded its Seattle, Washington-based subsidiary, Just - Evotec Biologics, Inc., an agreement worth 
USD28.6 million for the production of monoclonal antibodies ("mAbs") for use in the development of a treatment and/or 
prophylaxis for COVID-19. 
The DOD's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense ("JPEO-CBRND") is 
executing this effort in coordination with the Office of the Assistant Secretary of Defense for Health Affairs ("OASD 
(HA)") and the Defense Health Agency ("DHA"). 
Under the agreement, the DOD will have access to pivotal manufacturing capacity for anti-SARS-CoV-2 mAbs and priority 
access to future biomanufacturing capacity over a period of seven years in the soon-to-be-completed J.POD^(R) facility 
in Redmond, Washington. The agreement represents the continuation of DOD's collaboration with Just - Evotec Biologics. 
The collaboration started in July of 2020 and involved the selection of anti-SARS-CoV2 mAbs, resulting in rapid process 
development and manufacture of high yielding mAbs against SARS-CoV-2. 

https://www.marketscreener.com/quote/stock/EVOTEC-SE-436047/news/PRESS-RELEASE-Just-Evotec-Biologics-Expands-Contract-with-the-Department-of-Defense-for-Manufactu-32283987/